Biolamina

Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new collaborations
Endpoints
Thu, 05/17/18 - 10:04 am
Novo Nordisk
type 1 diabetes
stem cells
Biolamina